Secondary Prevention of Clostridioides Difficile Using Vancomycin | MicrobiomeTrials← Back to trialsNCT06979609
Secondary Prevention of Clostridioides Difficile Using Vancomycin
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-11-01Est. Completion: 2028-10-01
Enrollment target: 300 participants Locations- McGill University Health Centre, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection RecurrenceClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceCDIC. Diff InfectionRecurrent Clostridium Difficile InfectionC.Difficile DiarrheaDiarrhea Infectious
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…
Huntsville, United StatesEst. completion Jun 2027
The gut microbiota plays a crucial role in human health, influencing metabolism, immunity, and pathogen resistance. Rese…
Rome, ItalyEst. completion Mar 10, 2027
Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Multiple LocationsEst. completion Aug 22, 2028